Terms: = Prostate cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
73 results:
1. Association of hla-a*11:01, -A*24:02, and -B*18:01 with prostate cancer Risk: A Case-Control Study.
Manca MA; Simula ER; Cossu D; Solinas T; Madonia M; Cusano R; Sechi LA
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895076
[TBL] [Abstract] [Full Text] [Related]
2. The Prognostic Significance of Selected HLA Alleles on prostate cancer Outcome.
Stokidis S; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833904
[TBL] [Abstract] [Full Text] [Related]
3. A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps.
Foos G; Blazeska N; Nielsen M; Carter H; Kosaloglu-Yalcin Z; Peters B; Sette A
Hum Immunol; 2023 Nov; 84(11):578-589. PubMed ID: 37679223
[TBL] [Abstract] [Full Text] [Related]
4. The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer.
Roshan Zamir M; Ariafar A; Ghaderi A; Amirzargar A
Immunobiology; 2023 Mar; 228(2):152319. PubMed ID: 36599262
[TBL] [Abstract] [Full Text] [Related]
5. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.
Mao Z; Nesterenko PA; McLaughlin J; Deng W; Burton Sojo G; Cheng D; Noguchi M; Chour W; DeLucia DC; Finton KA; Qin Y; Obusan MB; Tran W; Wang L; Bangayan NJ; Ta L; Chen CC; Seet CS; Crooks GM; Phillips JW; Heath JR; Strong RK; Lee JK; Wohlschlegel JA; Witte ON
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2203410119. PubMed ID: 35878026
[TBL] [Abstract] [Full Text] [Related]
6. Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
Chen H; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Poon I; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):902-909. PubMed ID: 35753554
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer disease recurrence after radical prostatectomy is associated with HLA type and local cytomegalovirus immunity.
Classon J; Zamboni M; Engblom C; Alkass K; Mantovani G; Pou C; Nkulikiyimfura D; Brodin P; Druid H; Mold J; Frisén J
Mol Oncol; 2022 Oct; 16(19):3452-3464. PubMed ID: 35712787
[TBL] [Abstract] [Full Text] [Related]
8. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D; Wells A; Clark AM
Sci Rep; 2022 Apr; 12(1):6657. PubMed ID: 35459800
[TBL] [Abstract] [Full Text] [Related]
9. Splice-disrupt genomic variants in prostate cancer.
Alanazi IO; Alamery SF; Ebrahimie E; Mohammadi-Dehcheshmeh M
Mol Biol Rep; 2022 Jun; 49(6):4237-4246. PubMed ID: 35286517
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of Several Pathways for Efficient Killing of prostate cancer Stem Cells: A Central Role of NF-κB RELA.
Witte KE; Pfitzenmaier J; Storm J; Lütkemeyer M; Wimmer C; Schulten W; Czaniera N; Geisler M; Förster C; Wilkens L; Knabbe C; Mertzlufft F; Kaltschmidt B; Am Esch JS; Kaltschmidt C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445612
[TBL] [Abstract] [Full Text] [Related]
11. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
[TBL] [Abstract] [Full Text] [Related]
12. MHC Class I-Restricted TCR-Transgenic CD4
Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
[TBL] [Abstract] [Full Text] [Related]
13. Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
Jeon JM; Kwon OK; Na AY; Sung EJ; Cho IJ; Kim M; Yea SS; Chun SY; Lee JH; Ha YS; Kwon TG; Lee S
PLoS One; 2019; 14(8):e0220807. PubMed ID: 31404090
[TBL] [Abstract] [Full Text] [Related]
14. Primary human testicular PDGFRα+ cells are multipotent and can be differentiated into cells with Leydig cell characteristics in vitro.
Eliveld J; van den Berg EA; Chikhovskaya JV; van Daalen SKM; de Winter-Korver CM; van der Veen F; Repping S; Teerds K; van Pelt AMM
Hum Reprod; 2019 Sep; 34(9):1621-1631. PubMed ID: 31398257
[TBL] [Abstract] [Full Text] [Related]
15. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.
Depreter B; Weening KE; Vandepoele K; Essand M; De Moerloose B; Themeli M; Cloos J; Hanekamp D; Moors I; D'hont I; Denys B; Uyttebroeck A; Van Damme A; Dedeken L; Snauwaert S; Goetgeluk G; De Munter S; Kerre T; Vandekerckhove B; Lammens T; Philippé J
Haematologica; 2020 May; 105(5):1306-1316. PubMed ID: 31371409
[TBL] [Abstract] [Full Text] [Related]
16. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
[TBL] [Abstract] [Full Text] [Related]
17. A prospective and population-based inquiry on the use and acceptability of peer support for women newly diagnosed with breast cancer.
Legg M; Hyde MK; Occhipinti S; Youl PH; Dunn J; Chambers SK
Support Care Cancer; 2019 Feb; 27(2):677-685. PubMed ID: 30056530
[TBL] [Abstract] [Full Text] [Related]
18. A modified hla-a*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
[TBL] [Abstract] [Full Text] [Related]
19. cancer vaccine strategies: translation from mice to human clinical trials.
Berzofsky JA; Terabe M; Trepel JB; Pastan I; Stroncek DF; Morris JC; Wood LV
Cancer Immunol Immunother; 2018 Dec; 67(12):1863-1869. PubMed ID: 29143114
[TBL] [Abstract] [Full Text] [Related]
20. Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of prostate cancer.
Kalina JL; Neilson DS; Lin YY; Hamilton PT; Comber AP; Loy EMH; Sahinalp SC; Collins CC; Hach F; Lum JJ
Clin Cancer Res; 2017 Dec; 23(24):7596-7607. PubMed ID: 28954787
[No Abstract] [Full Text] [Related]
[Next]
